Chlorasquin inhibits thymidylate synthetase with an approximate Ki value of 4.9 µM. Chlorasquin is also a folate antagonist, testing the Methotrexate (HY-14519) effect. Chlorasquin binds tighter to dihydrofolate reductase at alkaline pH than does Methotrexate, which is promising for research of antipsoriatic agents[1][2].
